EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

L-Glutamine for Pediatric Sickle Cell Disease: Pharmacology, Mechanism of Action, Safety and Efficacy

Eduard H Panosyan

In Vivo · 2026-11 · 40 (6) · 3253-3261

DOI: 10.21873/invivo.14475 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift In Vivo, online erschienen am 29.10.2026. Verfasst von Eduard H Panosyan. Beteiligte Einrichtung: Division of Pediatric Hematology-Oncology, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, U.S.A.; epanosyan@lundquist.org. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Glutamine. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellGlutamineHumansAnimalsChildTreatment Outcome

Stichwörter der Autor:innen

Glutaminepharmacologyreviewsickle cell disease

Substanzen

Glutamine

Autor:innen und Institutionen

  • Division of Pediatric Hematology-Oncology, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, U.S.A.; epanosyan@lundquist.org.
  • The Lundquist Institute for Biomedical Innovation, Torrance, CA, U.S.A.

Zitieren

APA

Panosyan, E. H. (2026). L-Glutamine for Pediatric Sickle Cell Disease: Pharmacology, Mechanism of Action, Safety and Efficacy. In Vivo, 40(6), 3253-3261. https://doi.org/10.21873/invivo.14475

Vancouver

Panosyan EH. L-Glutamine for Pediatric Sickle Cell Disease: Pharmacology, Mechanism of Action, Safety and Efficacy. In Vivo. 2026;40(6):3253-3261. doi:10.21873/invivo.14475

BibTeX
@article{Panosyan2026,
  author = {Panosyan, Eduard H},
  title = {L-Glutamine for Pediatric Sickle Cell Disease: Pharmacology, Mechanism of Action, Safety and Efficacy},
  journal = {In Vivo},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {3253--3261},
  doi = {10.21873/invivo.14475}
}
Kostenlos starten →